ICON vs Medpace
ICLR and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICLR and MEDP compare
Medpace grew revenue faster over the last twelve months (20.4% versus 0.42% for ICON).
Medpace keeps more of each dollar of sales as profit, with a net margin of 18.2% compared with 5.4% at ICON.
Medpace scores higher on the StockData Score (14 against 7 for ICON), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICLR | MEDP |
|---|---|---|
| Size and price | ||
| Market cap | – | $18.3B |
| Share price | $195.02 | $653.09 |
| Change, 1 year | 20.2% | 10.7% |
| Change, 5 years | −28.3% | 211% |
| Beta (5Y) | 0.89 | 0.33 |
| Employees | 40K | 6,200 |
| StockData Score | ||
| Total score | 7 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 36.2× |
| P/S | – | 6.4× |
| P/B | – | 31.2× |
| EV/EBITDA | – | 28.9× |
| P/FCF | – | 27.4× |
| PEG | – | 1.29 |
| FCF yield | – | 3.7% |
| Fair value | – | $459.97 |
| Margin of safety | – | −42.0% |
| Growth | ||
| Revenue growth (TTM) | 0.42% | 20.4% (better) |
| Revenue growth, 5Y average | 24.2% (better) | 22.3% |
| Net income growth (TTM) | 19.7% (better) | 19.6% |
| EPS growth (TTM) | 30.0% (better) | 26.1% |
| EPS growth, 5Y average | −14.0% | 31.8% (better) |
| Profitability | ||
| Gross margin | 23.4% | – |
| Operating margin | 8.7% | 21.4% (better) |
| Net margin | 5.4% | 18.2% (better) |
| FCF margin | 10.4% | 23.5% (better) |
| Return on equity | 5.0% | 118% (better) |
| Return on invested capital | 4.9% | – |
| Financial health | ||
| Debt / equity | 0.37 (better) | 0.00 |
| Net debt / EBITDA | 2.37 | – |
| Interest coverage | 3.4× | – |
| Current ratio | 1.32 (better) | 0.83 |
| Altman Z-score | – | 8.13 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.6% |
| Shareholder yield | – | 1.6% |
| Ownership | ||
| Held by institutions | 105% | 88.3% |
| Held by insiders | 0.55% | 20.0% |
| Insider net buying, 12 months | −$8.2M (better) | −$262M |
| Superinvestors holding | 4 (better) | 2 |
| Short interest, % of float | 3.1% | 6.2% |
Go deeper
- ICLR stock overview
- ICLR income statement
- ICLR valuation and score
- MEDP stock overview
- MEDP income statement
- MEDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.